Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814907 | 0.79 | — | — | |
| SCHEMBL809407 | 0.79 | — | — | |
| SCHEMBL544740 | 0.77 | ALDH1A1 (0.60) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL7255546 | 0.77 | ALDH1A1 (0.60) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL374891 | 0.75 | ALDH1A1 (0.75) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL28897029 | 0.75 | ALDH1A1 (0.57) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL27787614 | 0.73 | ALDH1A1 (0.55) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL28676170 | 0.71 | ALDH1A1 (0.52) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL4576278 | 0.71 | ALDH1A1 (0.67) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL10748397 | 0.70 | SOAT1 (0.59) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118139851-A | Antitumor compounds | 法马马有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118059096-A | Methods of treating CNS disorders | 杭州高光制药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110650954-B | anticancer compounds | 法马马有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230104690-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIs) | BRANDON UNIV (CA) | 2023-04-06 | — | — | US | disclosed |
| CN-113226377-B | Antibody drug conjugates comprising an eltrinastine derivative | 法马马有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115003703-A | Hyaluronic acid derivatives | 麻省理工学院 | 2022-09-02 | — | — | CN | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005390-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041505-A2 | ANTHRANILIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042022-A1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042029-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0975632-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | Glycodesign Inc. (CA) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046602-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC. (CA) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104690-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIs) | MMP11, MMP9, MMP3 | ALDH1A1 611/4885SOAT1 3629/4885LMNA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.